Pancreatic cancer is an increasingly lethal cancer and is often diagnosed at an advanced stage. Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic malignant tumors and is known as the "king of cancers". The degree of malignancy is very high, making diagnosis and treatment difficult. This is because pancreatic ductal adenocarcinoma tissue contains a large amount of fibrous tissue in addition to ductal epithelial cell components. The existence of fibrous tissue results in poor blood supply for pancreatic cancer, making it difficult for chemotherapy drugs to enter, so the treatment effect is not ideal. So there is a need to develop new and more effective treatments to cure this disease.
Pancreatic Cancer Antibodies We Offer
Antibodies can be used to target cancer cells and prevent tumor growth and progression. Antibodies have been widely used in malignant tumor research, such as pancreatic cancer, breast cancer, colon cancer, non-small cell lung cancer, etc. Clinical studies have shown that antibody therapy can not only effectively kill focus cells, but also activate the human immune system to improve the body's defense against cancer, while reducing treatment side effects and improving patient survival rates. The essence of antibody therapy is to use specific monoclonal antibodies synthesized in vitro to achieve the purpose of treatment by identifying, binding and eliminating disease-related antigens or disease cells expressing antigens. Alfa Cytology has extensive experience in pancreatic cancer research and can provide you with antibody products suitable for your research project.
Alfa Cytology is committed to providing customers with antibody products with strong targeting, high stability, and obvious effects for pancreatic cancer research. We can recommend the best antibody options based on our customers' needs. If you are interested in our products, please contact us for more details.
P12FR2 aptamer sodium
Catalog No.: PC0022
Description: P12FR2 aptamer sodium is a 2'-fluoropyrimidine-modified RNA aptamer targeting human PAUF with an estimated apparent KD of 77 nM. The P12FR2 aptamer sodium inhibits PAUF-induced migration of PANC-1 (human pancreatic cancer cells) in a wound healing assay and suppresses tumor growth in a mouse CFPAC-1 pancreatic cancer model.
NIEA
Catalog No.: PC0023
Description: NIEA is a potent carcinogen that induce pancreatic cancer, esophageal cancer and hepatocellular carcinoma.
EAD1
Catalog No.: PC0024
Description: EAD1 is a potent autophagy inhibitor with antiproliferative activity in lung and pancreatic cancer cells. EAD1 also induces apoptosis.
SIRT6-IN-3
Catalog No.: PC0025
Description: SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC50=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cell proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) by blocking DNA damage repair pathways. SIRT6-IN-3 for pancreatic cancer research.
S100A2-p53-IN-1
Catalog No.: PC0026
Description: S100A2-p53-IN-1 (compound 51) is an inhibitor of the S100A2-p53 interaction. S100A2 is a Ca2+-binding protein involved in cell signaling and is known to be upregulated in pancreatic cancer. S100A2-p53-IN-1 can inhibit the growth of MiaPaCa-2 pancreatic cancer cell line (GI50 is 1.2-3.4 μM).
Clivatuzumab
Catalog No.: PC0027
Description: Clivatuzumab is a humanized anti-mucin monoclonal antibody that targets an epitope in the MUC1 antigen expressed in the majority of pancreatic cancers.
α-Thevetin B
Catalog No.: PC0028
Description: α-Thevetin B (Compound 24) is a cardiac glycoside that can be isolated from Thevetia peruviana. α-Thevetin B (Compound 24) can be used in the research of lung, gastric and pancreatic cancer.
FAK-IN-6
Catalog No.: PC0029
Description: FAK-IN-6 is a potent FAK inhibitor with an IC50 value of 1.415 nM. FAK-IN-6 has anti-proliferative activity against certain cancer cell lines. FAK-IN-6 can be used for researching pancreatic cancer.
SP-141
Catalog No.: PC0030
Description: SP-141 is a specific inhibitor of MDM2. SP-141 promotes MDM2 auto-ubiquitination and degradation. SP-141 might be used for the research of pancreatic cancer and breast cancer cells.
Glychionide A
Catalog No.: PC0031
Description: Glychionide A is a flavonoside that can be found in the roots of Glychirriza glabra. Glychionide A promotes apoptosis and autophagy of PANC-1 pancreatic cancer cells. Glychionide A can be used for the research of cancer.
Gastrazole
Catalog No.: PC0032
Description: Gastrazo (JB95008) is a potent and selective CCK2/gastrin receptor antagonist. Gastrozole can reduce stomach acid levels. Gastrin inhibits gastrin-stimulated pancreatic cancer growth.
Phellodendrine chloride
Catalog No.: PC0033
Description: Phellodendron is a plant alkaloid found in Phellodendron cypress. Phellodendrine chloride inhibits the proliferation of KRAS-mutated pancreatic cancer cells by inhibiting nutrient uptake through macropinocytosis. Phellodendron chloride promotes autophagy and alleviates intestinal damage in ulcerative colitis by regulating the AMPK/mTOR pathway.
Spiclomazine
Catalog No.: PC0034
Description: Spiclomazine (Clospirazine) is a potent mutant KRAS(G12C) inhibitor that selectively inhibits mutant KRAS-driven pancreatic cancer. Spiclomazine can eliminate KRas-GTP levels in KRAS-driven pancreatic cancer and effectively inhibit RAS-mediated signaling. Spiclomazine significantly inhibits tumor progression in mouse renal capsule xenotransplantation models.
NSC 48160
Catalog No.: PC0035
Description: NSC 48160 inhibits the growth of pancreatic cancer cells with an IC50 of 84.3 μM for CPFAC-1 and 94.5 μM for BxPC-3. NSC 48160 also induces apoptosis in pancreatic cancer cells. NSC 48160 can improve metabolic syndromes such as NASH, obesity and lipid metabolism disorders.
Garsorasib
Catalog No.: PC0036
Description: Garsorasib is a potent inhibitor of KRAS G12C with an IC50 of 10 nM. Garsorasib has the potential to study a variety of cancers, such as pancreatic, endometrial, colorectal or lung cancer (non-small cell lung cancer).
Carbidopa
Catalog No.: PC0037
Description: Carbidopa ((S)-(-)-Carbidopa), a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa inhibits pancreatic cancer cell and tumor growth.
Carbidopa monohydrate
Catalog No.: PC0038
Description: Carbidopa ((S)-(-)-carbidopa) monohydrate is a peripheral decarboxylase inhibitor used in the study of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cells and tumor growth.
Nardoguaianone K
Catalog No.: PC0039
Description: Nardoguaianone K is a guaiac-type compound isolated from spikenard roots. Nardoguaianone K is used in pancreatic cancer research.
PROTAC BRD4 Degrader-6
Catalog No.: PC0040
Description: PROTAC BRD4 Degrader-6 (Compound 32a) is a potent small molecule BRD4 degrader with an IC50 of 2.7 nM for BRD4 BD1. PROTAC BRD4 Degrader-6 efficiently degrades BRD4 protein and inhibits c-Myc expression. PROTAC BRD4 Degrader-6 inhibits proliferation and induces apoptosis in the pancreatic cancer cell line BxPC3. PROTAC BRD4 Degrader-6 can be used in human pancreatic cancer research.
MM41
Catalog No.: PC0041
Description: MM41 is a potent stabilizer of human telomeres and gene promoter DNA quadruplexes. MM41 is potent against the MIA PaCa-2 pancreatic cancer cell line with IC50 values <10 nM.
